Acrivon Therapeutics Unveils Preclinical Data Showing Strong Synergy in Cancer Treatments
Event summary
- Acrivon Therapeutics will present three posters at the 2026 AACR Annual Meeting, including one late-breaking presentation.
- ACR-368, a CHK1/2 inhibitor, showed potent preclinical synergy with Topoisomerase 1 inhibitors, common ADC payloads.
- ACR-2316, a WEE1/PKMYT1 inhibitor, demonstrated complete and durable tumor regression in combination with anti-PD-L1 checkpoint inhibition.
- The AACR Annual Meeting will be held in San Diego, CA from April 17-22, 2026.
The big picture
Acrivon Therapeutics' preclinical data highlights the potential of its AP3 platform to identify effective drug combinations, positioning the company at the forefront of precision oncology. The strong synergy observed in preclinical studies could pave the way for novel treatment regimens in cancer therapy, addressing key resistance mechanisms and enhancing therapeutic efficacy. The upcoming AACR Annual Meeting will provide a critical platform to validate these findings and attract potential partners or investors.
What we're watching
- Clinical Translation
- How the preclinical synergy of ACR-368 with Topo 1 inhibitors will translate into clinical outcomes.
- Regulatory Pathway
- Whether the promising data will accelerate the regulatory approval process for ACR-368 and ACR-2316.
- Market Positioning
- The pace at which Acrivon can establish itself as a leader in precision oncology through its AP3 platform.
Related topics